The pharmaceutical community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 receptor that’s exhibiting significant potential in clinical trials for managing obesity. Unlike some current weight loss solutions, retatrutide appears to deliver a greater substantial loss in body size and improve metabolic markers